Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ladiratuzumab vedotin + pembrolizumab in triple-negative breast cancer
NCT03310957Phase 2Completed
- Sponsor
- Seagen Inc.
- Start
- Feb 2018
- Primary completion
- Sep 2024
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 4
01
Overview
A Phase 2 trial of ladiratuzumab vedotin in triple-negative breast cancer (TNBC), sponsored by Seagen Inc.. Started Feb 2018; status: completed.
02
Drugs
ladiratuzumab vedotin
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT03310957.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03310957.